Pharmacological support strategies following endovenous laser ablation in patients with varicose veins
EVLA provides clinical improvement and reductions in inflammatory biomarkers, but the effect is less durable in advanced disease. MPFF primarily modulates MCP-1 and VEGF, while sulodexide acts on MMP-2 and MMP-9. Their combination shows complementary pathogenetic mechanisms, yielding the most durable biochemical and clinical benefits, and may represent the optimal pharmacological support for EVLA in patients with severe chronic venous disease.
Authors
- Igor Aleksandrovich Suchkov (ORCID: https://orcid.org/0000-0002-1292-5452)
- R.Е. Kalinin (ORCID: https://orcid.org/0000-0002-0817-9573)
- A.A. Kamaev (ORCID: https://orcid.org/0000-0002-3979-1271)
- А С Пшенников (ORCID: https://orcid.org/0000-0002-1687-332X)
Institutions
- Ryazan State Medical University named after Academician I.P. Pavlov (RU)
Publication Details
- Journal
- Pirogov Russian Journal of Surgery
- Published
- 2025-12-19
- DOI
- https://doi.org/10.17116/hirurgia2025121119
- Primary Topic
- Diagnosis and Treatment of Venous Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00